{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-307318","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2022-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.632350+00:00","generated_at":"2026-06-21T03:37:30.410828+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biomea Fusion receives FDA IND clearance for BMF-219 in type 2 diabetes; expands COVALENT-111 to US sites","bullets":["FDA cleared IND for BMF-219 (covalent menin inhibitor) in type 2 diabetes; will activate US sites in ongoing COVALENT-111 study.","Phase I portion completed with favorable safety, PK, and PD profile.","Phase II portion evaluating BMF-219's ability to restore beta-cell health and long-term glycemic control.","Initial Phase II data expected in first half of 2023.","Company to host investor conference call on December 15, 2022 at 4 PM EST."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-307318","json":"https://secwatch.observer/filing/0001193125-22-307318.json","markdown":"https://secwatch.observer/filing/0001193125-22-307318.md","text":"https://secwatch.observer/filing/0001193125-22-307318.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312522307318/0001193125-22-307318-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312522307318/d426454d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T03:37:30.410828+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}